Vivani Medical, Inc.

NASDAQ:VANI

Medical - Devices

Healthcare
$1.05 +1.30%

+$0.02 today

Market cap
$94.71M
Beta
3.29
P/E (TTM)
-3.5
EPS (TTM)
-$0.33
52W Low $0.92High $1.92

Volume 0.18M

Average 0.24M

VANI Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Vivani Medical, Inc.NASDAQ: VANI

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$43K, compared with $78K a year earlier. Trailing-twelve-month accounts receivables was -$522K.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$43K or moves back toward the trailing-twelve-month quarterly average of -$130.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43K-530.0% QoQ
Last fiscal yearDec 2025
-$401K— YoY
LTMMar 2026
-$522K-769.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-155.1%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(401K) USD
Year-over-year change
—

Accounts Receivables vs competitors

How VANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -769.2% is the lowest of 6, against a peer median of +162.7%.
VANI Competitors
Accounts Receivables for VANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$7.22M USD-27.6%+17.3%6.9%
RCELAVITA Medical, Inc.LTM Mar 2026$3.09M USD+162.7%—4.3%
HYPRHyperfine, Inc.LTM Mar 2026$1.47M USD+242.9%—9.6%
VANIVivani Medical, Inc.LTM Mar 2026$522K USD-769.2%——
MBOTMicrobot Medical Inc.LTM Mar 2026$105K USD——100.0%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$6.69K CAD+227.1%——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD———
IMAImageneBio IncLTM Mar 2026$0 USD+100.0%——
Peer median (excluding VANI) —+162.7%+17.3%8.2%

Competitors are the stored peer set for VANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.77M)(13.89M)(25.65M)(23.49M)(26.61M)
Depreciation & Amortization345K381K357K400K424K
Deferred Income Tax00000
Stock-Based Compensation1.67M1.3M1.86M1.61M1.48M
Change in Working Capital436K338K(1.29M)354K229K
Accounts Receivables0000(401K)
Inventory00000
Accounts Payables13K(1.94M)(602K)248K(222K)
Other Working Capital423K2.28M(691K)106K852K
Other Non-Cash Items(627K)(6.91M)1.03M336K152K
Operating Cash Flow(10.95M)(18.79M)(23.7M)(20.79M)(24.32M)
Capital Expenditures(572K)(338K)(887K)(556K)(1.17M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(572K)(338K)(887K)(556K)(1.17M)
Debt Repayment08M019.05M11K
Common Stock Issued11.62M16K133K18.82M23.29M
Common Stock Repurchased0000(28K)
Dividends Paid00000
Other Financing Activities055.37M0(18.82M)0
Financing Cash Flow11.62M63.39M133K19.05M23.27M
Effect of Forex Changes(1.1M)(1K)3K(14K)99K
Net Change in Cash97K44.26M(24.45M)(2.3M)(2.12M)
Free Cash Flow(11.52M)(19.13M)(24.59M)(21.34M)(25.49M)

Vivani Medical, Inc.

NASDAQ:VANI

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.